Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isotechnika has announced that Roche has given up its rights to license voclosporin for solid organ transplant. This allows Isotechnika to open up the opportunity to license voclosporin to potential partners for both transplant and autoimmune indications.
Subscribe to our email newsletter
Isotechnika will now open up the licensing process to companies with a strategic focus in this therapeutic area. The licensing process will be completed based on an accelerated schedule that takes Isotechnika’s interests and current market conditions into account.
Voclosporin is said to be a unique opportunity for partners focused on growing in a very significant market and looking to strengthen their pipeline by adding a late stage product with excellent commercial potential.
Robert Foster, chairman and CEO of Isotechnika, said: “Adding transplant to the list of available indications will greatly strengthen our position and improve the attractiveness of the opportunity to potential partners.”